Innoviva (INVA) Cash from Operations (2010 - 2026)
Innoviva posted quarterly Cash from Operations of 35282000.0 for Q1 2026, down 27.43% year-on-year from 48617000.0 in Q1 2025, and down 75.23% on a QoQ basis from 142417000.0 in Q3 2025.
Innoviva (INVA) has 17 years of Cash from Operations data on file, last reported at 35282000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 27.43% year-over-year to 35282000.0; the trailing twelve-month figure through Mar 2026 stood at 270389000.0 (up 4.46% YoY), and the FY2025 full-year result was 196930000.0, up 4.37% from the prior year.
- Cash from Operations for Q1 2026 stood at 35282000.0, down from 142417000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 192827000.0 in Q3 2022 and bottomed at 25684000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 48617000.0 (2025), against an average of 78634076.92.
- The widest annual swing landed in 2023, when Cash from Operations plunged 73.82%; it then jumped 44.24% in 2024.
- A 5-year view of Cash from Operations shows it stood at 192827000.0 in 2022, then tumbled by 44.09% to 107808000.0 in 2023, then advanced by 20.08% to 129451000.0 in 2024, then climbed by 10.02% to 142417000.0 in 2025, then slumped by 75.23% to 35282000.0 in 2026.
- The last three Cash from Operations figures came in at 35282000.0 (Q1 2026), 142417000.0 (Q3 2025), and 44073000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 35.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.28 Mn |
| Mar 31, 2026 | 35.28 Mn |
| Sep 30, 2025 | 142.42 Mn |
| Sep 30, 2025 | 142.42 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Sep 30, 2024 | 129.45 Mn |
| Sep 30, 2024 | 129.45 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Sep 30, 2023 | 107.81 Mn |
| Sep 30, 2023 | 107.81 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Mar 31, 2023 | 25.68 Mn |
| Mar 31, 2023 | 25.68 Mn |
| Sep 30, 2022 | 192.83 Mn |
| Sep 30, 2022 | 192.83 Mn |
| Jun 30, 2022 | 79.04 Mn |
| Jun 30, 2022 | 79.04 Mn |
| Mar 31, 2022 | 98.10 Mn |
| Mar 31, 2022 | 98.10 Mn |
| Sep 30, 2021 | 265.43 Mn |
| Sep 30, 2021 | 265.43 Mn |
| Jun 30, 2021 | 84.61 Mn |
| Jun 30, 2021 | 84.61 Mn |
| Mar 31, 2021 | 84.11 Mn |
| Mar 31, 2021 | 84.11 Mn |
| Dec 31, 2020 | 85.28 Mn |
| Dec 31, 2020 | 85.28 Mn |
| Sep 30, 2020 | 74.56 Mn |
| Sep 30, 2020 | 74.56 Mn |
| Jun 30, 2020 | 79.79 Mn |
| Jun 30, 2020 | 79.79 Mn |
| Mar 31, 2020 | 73.48 Mn |
| Mar 31, 2020 | 73.48 Mn |
| Dec 31, 2019 | 66.91 Mn |
| Dec 31, 2019 | 66.91 Mn |
| Sep 30, 2019 | 57.40 Mn |
| Sep 30, 2019 | 57.40 Mn |
| Jun 30, 2019 | 56.50 Mn |
| Jun 30, 2019 | 56.50 Mn |
| Mar 31, 2019 | 76.66 Mn |
| Mar 31, 2019 | 76.66 Mn |
| Dec 31, 2018 | 61.78 Mn |
| Dec 31, 2018 | 61.78 Mn |
| Sep 30, 2018 | 60.12 Mn |
| Sep 30, 2018 | 60.12 Mn |
| Jun 30, 2018 | 51.73 Mn |
| Jun 30, 2018 | 51.73 Mn |
| Mar 31, 2018 | 49.91 Mn |
| Mar 31, 2018 | 49.91 Mn |
| Dec 31, 2017 | 47.86 Mn |
| Dec 31, 2017 | 47.86 Mn |
| Sep 30, 2017 | 43.49 Mn |
| Sep 30, 2017 | 43.49 Mn |
| Jun 30, 2017 | 22.64 Mn |
| Jun 30, 2017 | 22.64 Mn |
| Mar 31, 2017 | 27.76 Mn |
| Mar 31, 2017 | 27.76 Mn |
| Dec 31, 2016 | 21.09 Mn |
| Dec 31, 2016 | 21.09 Mn |
| Sep 30, 2016 | 20.19 Mn |
| Sep 30, 2016 | 20.19 Mn |
| Jun 30, 2016 | 12.46 Mn |
| Jun 30, 2016 | 12.46 Mn |
| Mar 31, 2016 | 7.25 Mn |
| Mar 31, 2016 | 7.25 Mn |
| Dec 31, 2015 | 6.92 Mn |
| Dec 31, 2015 | 6.92 Mn |
| Sep 30, 2015 | 2.66 Mn |
| Sep 30, 2015 | 2.66 Mn |
| Jun 30, 2015 | 2.17 Mn |
| Jun 30, 2015 | 2.17 Mn |
| Mar 31, 2015 | -1.62 Mn |
| Mar 31, 2015 | -1.62 Mn |
| Dec 31, 2014 | -4.61 Mn |
| Dec 31, 2014 | -4.61 Mn |
| Sep 30, 2014 | -21.07 Mn |
| Sep 30, 2014 | -21.07 Mn |
| Jun 30, 2014 | -54.41 Mn |
| Jun 30, 2014 | -54.41 Mn |
| Mar 31, 2014 | -50.64 Mn |
| Mar 31, 2014 | -50.64 Mn |
| Dec 31, 2013 | -39.97 Mn |
| Dec 31, 2013 | -39.97 Mn |
| Sep 30, 2013 | -41.31 Mn |
| Sep 30, 2013 | -41.31 Mn |
| Jun 30, 2013 | -16.69 Mn |
| Jun 30, 2013 | -16.69 Mn |
| Mar 31, 2013 | -31.63 Mn |
| Mar 31, 2013 | -31.63 Mn |
| Dec 31, 2012 | -24.25 Mn |
| Dec 31, 2012 | -24.25 Mn |
| Sep 30, 2012 | -27.57 Mn |
| Sep 30, 2012 | -27.57 Mn |
| Jun 30, 2012 | -34.37 Mn |
| Jun 30, 2012 | -34.37 Mn |
| Mar 31, 2012 | -41.33 Mn |
| Mar 31, 2012 | -41.33 Mn |
| Dec 31, 2011 | -25.36 Mn |
| Dec 31, 2011 | -25.36 Mn |
| Sep 30, 2011 | -19.33 Mn |
| Sep 30, 2011 | -19.33 Mn |
| Jun 30, 2011 | -17.76 Mn |
| Jun 30, 2011 | -17.76 Mn |
| Mar 31, 2011 | -25.89 Mn |
| Mar 31, 2011 | -25.89 Mn |
| Dec 31, 2010 | -15.07 Mn |
| Dec 31, 2010 | -15.07 Mn |
| Sep 30, 2010 | -19.19 Mn |
| Sep 30, 2010 | -19.19 Mn |